Nurse Practitioner in Pacifica, CA Accepting Medicare
8 Nurse Practitioner nurses found. Showing 1 - 8
 Ms. Frances Marie Devlin, N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1520 Madeira Dr, Pacifica, CA 94044 Phone: 650-359-8745 |
Phyllis Melvin, R.N.,N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1520 Madeira Dr, Pacifica, CA 94044 Phone: 650-359-8745 |
Beth N Chopra, RN, MSN, CPNP Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 340 Eureka Sq, Pacifica, CA 94044 Phone: 650-359-1675 |
Lisa Marie Lee, CPNP Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: 340 Eureka Drive, Pacifica, CA 94044 Phone: 650-359-1675 |
Katherine Ryan Goetzke, CFNP Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: 340 Eureka Sq, Pacifica, CA 94044 Phone: 650-453-3467 |
Rebecca Kaplan Chambliss, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1183 Cervantes Way, Pacifica, CA 94044 Phone: 650-451-8853 |
Felcynth May Destura Marquez, NP, CNS, RN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 170 Crestmoor Cir, Pacifica, CA 94044 Phone: 650-219-3726 |
Barbette Murphy, RN, MS, PNP Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 340 Eureka Sq, Pacifica, CA 94044 Phone: 650-359-1675 |
News Archive
Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced the launch of Hereditary Colorectal Cancer DNA Insight, the company's premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient's risk of developing certain types of cancer.
One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture
More than 53 million Americans age 50 and older, primarily women, have osteoporosis or are at high risk for the condition due to low bone density. A recent study of oral bisphosphonates, the most commonly prescribed osteoporosis treatment, found that approximately a third of women prescribed these drugs continue to be at elevated risk for bone fracture, an outcome that may have several origins.
Tributyltin exposure may cause ‘transgenerational obesity'
Research shows that offspring of mice exposed to low doses of the chemical tributyltin, used in paints, plastics, and other consumer products, have greater than normal body fat, liver fat, and fat-specific gene expression.
New vaccine for post exposure treatment of rabies infection enters human clinical trial
Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide.
› Verified 8 days ago